# A Trial to Study BAY1753011 in Patients With Congestive Heart Failure

Study · id `cardio:ct-nct03901729` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03901729](<https://clinicaltrials.gov/study/NCT03901729>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03901729

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 482 participants.

## Technical summary

Registry record NCT03901729. Randomized; quadruple masking; primary purpose treatment. Start 2019-05-29 (actual); primary completion 2021-04-16 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 482 participants (enrolled count; ClinicalTrials.gov record NCT03901729, source copy `cardio:ctgov-nct03901729-2022-04-18`, retrieved 2026-10-26)
- Started: 2019-05-29 (actual) (ClinicalTrials.gov record NCT03901729, source copy `cardio:ctgov-nct03901729-2022-04-18`, retrieved 2026-10-26)
- Primary completion: 2021-04-16 (actual) (ClinicalTrials.gov record NCT03901729, source copy `cardio:ctgov-nct03901729-2022-04-18`, retrieved 2026-10-26)
- Completion: 2021-05-21 (actual) (ClinicalTrials.gov record NCT03901729, source copy `cardio:ctgov-nct03901729-2022-04-18`, retrieved 2026-10-26)
- Countries: Austria; Bulgaria; Greece; Hungary; Israel; Italy; Poland; Portugal; Spain (ClinicalTrials.gov record NCT03901729, source copy `cardio:ctgov-nct03901729-2022-04-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03901729-2022-04-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Trial to Study BAY1753011 in Patients With Congestive Heart Failure
- Acronym: AVANTI
- Condition: Heart Failure (HF)
- Intervention (Drug): BAY 1753011
- Intervention (Other): Placebo BAY 1753011
- Intervention (Drug): Furosemide
- Intervention (Other): Placebo Furosemide
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A multicentre, randomized, double-blind, active and placebo-controlled study of pecavaptan, a dual V1a/V2 vasopressin receptor antagonist, in patients with acute heart failure: The AVANTI trial (`cardio:pubmed-40788619`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c4bb11ed39b3b10247768a4db338699b6c9bce3a338fefdb9809b96c00833163
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
